Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-21T02:10:07.062Z Has data issue: false hasContentIssue false
  • English
  • Français

Epidemiology of Guillain-Barré Syndrome in the Province of Quebec

Published online by Cambridge University Press:  02 December 2014

Geneviève Deceuninck ,
Renée-Myriam Boucher ,
Philippe De Wals  and
Manale Ouakki
Geneviève Deceuninck
Affiliation:
Public Health Research Unit, Quebec University Hospital Centre, Quebec City, Canada
Renée-Myriam Boucher
Affiliation:
Department of Paediatric Neurology, Quebec City, Canada
Philippe De Wals*
Affiliation:
Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
Manale Ouakki
Affiliation:
Quebec National Public Health Institute, Quebec City, Canada
*
Département de Médecine sociale et préventive, Université Laval, Pavillon de l’Est, 2180 chemin Sainte–Foy, Suite 1108, Québec, Canada, G1K 7P4.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

In the province of Quebec, a population-based study of Guillain-Barré syndrome (GBS) was conducted at the time of a mass immunization campaign against meningococcal disease, in 2001.

Methods:

The study population included residents aged 2 months to 20 years observed from November 1st, 2000 to December 31, 2002, representing 4 075 465 person-years of observation. GBS cases were identified in the provincial hospital database Med-Echo and medical records were reviewed.

Results:

Thirty-three incident GBS cases were identified, including 27 cases of acute inflammatory demyelinating polyradiculopathy. The overall GBS incidence rate was 0.8/100 000 person-years, higher in persons aged 1 to 4 years (2.1/100 000) than in those 5 years or more (0.6/100 000). There was a female preponderance and no significant seasonal variation. All patients survived.

Conclusion:

Results could be used to interpret reports of adverse events associated with the introduction of new vaccines in this age-group in Canada.

Résumé:

RÉSUMÉ:Contexte:

Nous avons effectué une étude de population sur le syndrome de Guillain–Barré (SGB) dans la province de Québec au moment d’une campagne d’immunisation de masse contre le méningocoque en 2001.

Méthodes:

Les résidents âgés de 2 mois à 20 ans ont été inclus dans l’étude entre le premier novembre 2000 et le 31 décembre 2002, soit 4,075,465 personnes–années d’observation. Les cas de SGB ont été identifiés dans la base de données hospitalières provincial Med–Écho et les dossiers médicaux ont été analysés.

Résultats:

33 nouveaux cas de SGB ont été identifiés dont 27 cas de polyradiculopathie démyélinisante inflammatoire aiguë. Le taux d’incidence global du SGB était de 0,8/100,000 personnes–années, un taux plus élevé chez les enfants de 1 à 4 ans (2,1/100,000) que chez les enfants âgés de 5 ans ou plus (0,6/100,000), avec une prédominance féminine. Aucune variation saisonnière significative n’a été observée. Tous les patients ont survécu.

Conclusion:

Ces résultats pourraient être utilisés dans l’interprétation de rapports d’effets indésirables associés à l’introduction de nouveaux vaccins dans ce groupe d’âge au Canada.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 35 , Issue 4 , September 2008 , pp. 472 - 475
Copyright
Copyright © The Canadian Journal of Neurological 2008

References

1. Hahn, A. Guillain-Barré syndrome. Lancet. 1998; 352: 635–41.CrossRefGoogle ScholarPubMed
2. Hughes, RA, Cornblath, DR. Guillain-Barré syndrome. Lancet. 2005; 366: 1653–66.CrossRefGoogle ScholarPubMed
3. Langmuir, AD, Bregman, DJ, Kurland, LT, Nathanson, N, Victor, M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984; 119: 841–79.CrossRefGoogle ScholarPubMed
4. Lasky, T, Terracciano, GJ, Magder, L, Koski, CL, Ballesteros, M, Nash, D, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998; 339: 1797–802.CrossRefGoogle ScholarPubMed
5. Stratton, KR, Howe, CJ, Johnston, RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the institute of medicine. JAMA. 1994; 271: 1602–5.CrossRefGoogle ScholarPubMed
6. Hughes, RA, Charlton, J, Latinovic, R, Gulliford, MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006; 166: 1301–4.CrossRefGoogle ScholarPubMed
7. Woo, EJ, Ball, R, Braun, M, Clark, T, Rosenstein Messonnier, N, Wharton, M, et al. Update: Guillain-Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine-United States, June 2005-Sepember 2006. MMWR. 2006; 55 (41): 1120–4.Google Scholar
8. Siegrist, CA. Autoimmune diseases after adolescent or adult immunization: What should we expect? CMAJ. 2007; 177: 1352–4.CrossRefGoogle ScholarPubMed
9. DeWals, P, Deceuninck, G, Boulianne, N, De Serres, G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA. 2004; 292: 2491–4.CrossRefGoogle Scholar
10. De Wals, P, Deceuninck, G, Boucher, RM, Ouakki, M. Risk of Guillain-Barré syndrome following serogroup C Meningococcal conjugate vaccine in Quebec, Canada. Clin Infect Dis. In press.CrossRefGoogle Scholar
11. Assemblée nationale. Loi sur la santé publique. Québec city (province of Quebec, Canada): Editeur officiel du Québec, 2001.Google Scholar
12. The Brighton Collaboration GBS Working Group. The Brighton Collaboration Guillain Barre’ Syndrome case definition draft, version 20. Atlanta, GA [updated 2007 September 12; accessed 2008 March 13]. Available from: http://www.brightoncollaboration.org/internet/en/index/definition___guidelines/document_download.htmlGoogle Scholar
13. Bogliun, G, Beghi, E, Guillain-Barré, . Syndrome Registry Study Group. Validity of hospital discharge diagnoses for public health surveillance of the Guillain-Barré syndrome. Neurol Sci. 2002; 23: 113–7.CrossRefGoogle Scholar
14. Mclean, M, Duclos, P, Jacob, P, Humphreys, P. Incidence of Guillain- Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology. 1994; 5: 443–8.CrossRefGoogle ScholarPubMed
15. Hauck, LJ, White, C, Feasby, TE, Zochodne, DW, Svenson, LW, Hill, MD. Incidence of Guillain-Barré syndrome in Alberta, Canada: an administrative data study. Neurol Neurosurg Psychiatry. In Press 2007.Google Scholar
16. Kaplan, JE, Schonberger, LB, Hurwitz, ES, Katona, P. Guillain-Barré syndrome in the United States, 1978-1981: additional observations from the national surveillance system. Neurology. 1983; 33: 633–7.CrossRefGoogle ScholarPubMed
17. Prevots, DR, Sutter, RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis. 1997;175 Suppl 1: S151–5.CrossRefGoogle ScholarPubMed
18. Navarro, C, Deeks, SL, Medaglia, A, Tsang, RSW. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. CCDR. 2007; 33 (10): 1–15.Google Scholar